Last reviewed · How we verify
JMT108
At a glance
| Generic name | JMT108 |
|---|---|
| Sponsor | Shanghai JMT-Bio Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors (PHASE1, PHASE2)
- A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors (PHASE1)
- Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMT108 CI brief — competitive landscape report
- JMT108 updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI